Name | Number of supported studies | Average coverage | |
---|---|---|---|
respiratory goblet cell | 7 studies | 56% ± 15% | |
club cell | 6 studies | 36% ± 20% | |
deuterosomal cell | 4 studies | 26% ± 13% | |
secretory cell | 3 studies | 39% ± 11% |
Insufficient scRNA-seq data for expression of CYP2F1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 76% | 136.56 | 439 / 578 | 18% | 1.45 | 211 / 1155 |
esophagus | 37% | 25.38 | 536 / 1445 | 6% | 0.11 | 11 / 183 |
ovary | 3% | 0.17 | 5 / 180 | 18% | 1.13 | 77 / 430 |
tonsil | 0% | 0 | 0 / 0 | 13% | 0.52 | 6 / 45 |
uterus | 4% | 0.36 | 6 / 170 | 8% | 0.61 | 37 / 459 |
intestine | 6% | 0.44 | 62 / 966 | 4% | 0.06 | 21 / 527 |
stomach | 3% | 0.18 | 9 / 359 | 6% | 0.27 | 17 / 286 |
breast | 5% | 0.46 | 25 / 459 | 3% | 0.21 | 33 / 1118 |
peripheral blood | 7% | 0.88 | 64 / 929 | 0% | 0 | 0 / 0 |
adipose | 6% | 0.43 | 72 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 6% | 0.37 | 15 / 258 | 0% | 0 | 0 / 230 |
thymus | 6% | 0.39 | 37 / 653 | 0% | 0 | 0 / 605 |
bladder | 0% | 0 | 0 / 21 | 5% | 0.38 | 25 / 504 |
skin | 4% | 0.29 | 74 / 1809 | 1% | 0.02 | 3 / 472 |
spleen | 4% | 0.25 | 10 / 241 | 0% | 0 | 0 / 0 |
prostate | 4% | 0.43 | 9 / 245 | 0% | 0 | 0 / 502 |
blood vessel | 3% | 0.22 | 42 / 1335 | 0% | 0 | 0 / 0 |
pancreas | 1% | 0.04 | 2 / 328 | 2% | 0.10 | 3 / 178 |
brain | 2% | 0.13 | 51 / 2642 | 0% | 0.02 | 2 / 705 |
kidney | 1% | 0.06 | 1 / 89 | 0% | 0.02 | 4 / 901 |
heart | 2% | 0.10 | 13 / 861 | 0% | 0 | 0 / 0 |
liver | 1% | 0.14 | 3 / 226 | 0% | 0 | 0 / 406 |
muscle | 1% | 0.07 | 6 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1901170 | Biological process | naphthalene catabolic process |
GO_0019373 | Biological process | epoxygenase P450 pathway |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0009636 | Biological process | response to toxic substance |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005737 | Cellular component | cytoplasm |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0019825 | Molecular function | oxygen binding |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008392 | Molecular function | arachidonic acid epoxygenase activity |
GO_0020037 | Molecular function | heme binding |
GO_0070330 | Molecular function | aromatase activity |
GO_0016712 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
Gene name | CYP2F1 |
Protein name | Cytochrome P450 2F1 (EC 1.14.14.1) (CYPIIF1) Cytochrome P450 family 2 subfamily F member 1 Truncated cytochrome P450 2F1 variant |
Synonyms | |
Description | FUNCTION: May be involved in the metabolism of various pneumotoxicants including naphthalene. Is able to dealkylate ethoxycoumarin, propoxycoumarin, and pentoxyresorufin but possesses no activity toward ethoxyresorufin and only trace dearylation activity toward benzyloxyresorufin. Bioactivates 3-methylindole (3MI) by dehydrogenation to the putative electrophile 3-methylene-indolenine. . |
Accessions | H0YGI9 P24903 A7KAU4 ENST00000439903.2 ENST00000532164.2 [P24903-2] ENST00000534009.1 ENST00000331105.7 [P24903-1] A0A075B795 |